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Background: Maturity-onset diabetes of the young type 8 (MODY8 or CEL-MODY) is an inherited
pancreatic disease characterized by chronic inflammation of the pancreas and diabetes. It is not known
whether MODY8 patients have increased risk for developing pancreatic cancer. We investigated KRAS
mutation load in duodenal juice from MODY8 patients, comparing with other groups of pancreatic
disease.
Methods: Droplet digital PCR (ddPCR) was used to detect KRAS codon 12/13/61 mutations in duodenal
juice sampled from 11 MODY8 patients, nine healthy subjects and 100 patients clinically investigated due
to suspected pancreatic disease.
Results: KRAS mutations were detected in 4/11 patients with MODY8 (36%), 1/9 healthy subjects (11%),
15/44 patients with chronic pancreatitis (CP, 34%), 3/5 patients with pancreatic ductal adenocarcinoma
(PDAC, 60%), 3/20 patients with acute pancreatitis (15%), 0/13 patients with other pancreatic disorders
and 2/18 patients with nonpancreatic gastrointestinal disease (11%). Of the 28 positive juice samples, 25
(89%) had low-abundance mutations in codons 12/13, with a variant allele frequency (VAF) less than 1%.
KRAS-positive patients with MODY8 or CP had significantly lower VAFs than patients with PDAC (Mann-
Whitney U test; p ¼ 0.041). Although the overall mutation detection rate was higher for subjects 50
years old (26%) than for younger subjects (15%), the difference was not statistically significant.
Conclusions: KRAS mutations were detectable in duodenal juice from MODY8 patients, but with low
abundance and at the same frequency as in CP patients. The discriminative value of the analysis with
regard to other pancreatic disease was limited.
© 2021 The Authors. Published by Elsevier B.V. on behalf of IAP and EPC. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Among monogenic diabetes forms, maturity-onset diabetes of
the young, type 8 (MODY8) is unique as the primary defect arises in
the exocrine tissue and not in the islets of Langerhans [1]. The
disease is caused by mutations in the CEL gene which encodes
carboxyl ester lipase, a digestive enzyme specifically produced bylogy, Department of Clinical
021 Bergen, Norway.
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Pancreatology, https://doi.orthe pancreatic acinar cells [2,3]. The parenchyma of the MODY8
pancreas is characterized by lipomatosis, atrophy, fibrosis and
cystic lesions [2,4,5], and the patients exhibit pancreatic exocrine
insufficiency early in life with onset of diabetes in their 30ies or
40ies [2]. Thus, MODY8 may also be regarded as a form of heredi-
tary chronic pancreatitis (CP) in which secondary diabetes
frequently develops.
Patients with CP, especially inherited forms, have an increased
risk for developing pancreatic cancer [6]. After the publication of
the first report onMODY8 [2], one family member developed KRAS-
positive pancreatic ductal adenocarcinoma (PDAC) at age 78 [5]. Wehis is an open access article under the CC BY license (http://creativecommons.org/
tation analysis by droplet digital PCR of duodenal juice from patients
g/10.1016/j.pan.2021.09.010
M.H. Choi, E. Tjora, R.B. Forthun et al. Pancreatology xxx (xxxx) xxxtherefore asked the question whether the long-standing patho-
genic process of MODY8, which also includes cyst formation in the
pancreas, predisposes for development of pancreatic malignancy
later in life.
This problem might be addressed by searching for circulating
tumor DNA (ctDNA) in pancreatic secretions from the patients.
Sampling of pancreatic juice from the duodenum upon secretin
stimulation (hereafter termed “duodenal juice”) is clinically feasible
and relatively safe, and can be integrated into other diagnostic
procedures for patients with suspected pancreatic disease. More-
over, oncogenic KRAS mutations are early somatic events in the
development of PDAC, and several studies have shown that KRAS
mutations can be frequently detected in pancreatic secretions from
PDAC patients [7e10]. The detection of somatic KRAS mutations in
pancreatic secretions therefore represents a potential screening
approach to identify the emerging cancer at a curable stage [11].
In this study, we used the highly sensitive droplet digital PCR
technique (ddPCR) [12] to detect and quantify KRAS mutations in
duodenal juice obtained from MODY8 patients. For comparison, we
included juice samples collected as part of the diagnostic workup in
various other patient groups. We found that KRAS mutations were
detectable insomeof theMODY8duodenal juice samples,butnotwith
a higher abundance than in CP patients. In addition, our study high-
lights challenges of using duodenal juice for early cancer detection.2. Methods
2.1. Collection of duodenal juice samples
We analyzed duodenal juice samples obtained from 11 MODY8
patients, all being mutation carriers that belong to the largest
Norwegian family described in Ræder et al. [2]. Duodenal juice was
also collected from 100 other patients as part of their clinical
workup at Haukeland University Hospital, Bergen, Norway be-
tween 2010 and 2012 (Table 1). KRAS-positive MODY8 patients and
patients with high mutational load had their medical records
checked in 2020 for development of pancreatic neoplastic disease.
Moreover, duodenal juice was sampled from nine healthy controls
for the purpose of this and other research projects. Secretion of
duodenal juice was stimulated by administration of secretin, and
the juice was collected endoscopically as described [13]. The juice
samples were immediately aliquoted and stored in liquid nitrogen
until further use. This study was performed in accordance with the
Helsinki II Declaration and was approved by the Research Ethics
Committee of Western Norway (REK Vest 2010/198). Written
informed consent was obtained from all study participants.2.2. DNA isolation and quantification
DNA was extracted from duodenal juice using the QIAamp DNA
Investigator kit (Qiagen) according to the manufacturer'sTable 1
Overview of the subject groups included in the study.
Subject groups Number of subjects
Maturity-onset diabetes of the young, type 8 11
Chronic pancreatitis 44
Pancreatic ductal adenocarcinoma 5
Acute pancreatitis 20
Other pancreatic disordersa 13
Nonpancreatic gastrointestinal disease 18
Healthy controls 9
a This group included germline CEL-HYB mutation [25,26] without chronic pancreati
diabetes mellitus type 1.
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instructions, but with some minor modifications as follows: The
juice samplewasmixedwith an equal volume of Buffer AL, with the
proteinase K solution of the kit (20 mg/ml) added at one-tenth of
the starting juice volume. This solutionwas incubated at 56 C with
shaking for 10 min. After addition of ethanol (50 ml per 100 ml of
starting juice volume), the solution was incubated at room tem-
perature for 3 min and then applied to the QIAamp MinElute col-
umn supplied by the kit. The column was centrifuged, and washed
separately with Buffer AW1, Buffer AW2 and ethanol. When the
column had dried, DNA was eluted in Buffer ATE and stored
at 20 C until use. DNA concentration was measured on the Qubit
V 3.0 fluorometer using the Qubit dsDNA BR Assay kit (Thermo
Fisher Scientific).2.3. Protein quantification
The protein concentration of each duodenal juice was deter-
mined on the Qubit V 3.0 fluorometer using the Qubit Protein Assay
kit (Thermo Fisher Scientific) according to the manufacturer's
protocol.2.4. ddPCR assay
KRAS mutations in duodenal juice DNA were detected using the
ddPCR KRAS G12/G13 Screening kit (Bio-Rad, #1863506), which
detects seven different nonsynonymous mutations in codons 12 and
13 (p.G12A, p.G12C, p.G12D, p.G12R, p.G12S, p.G12V and p.G13D)
and thewildtype allele. For KRAS codon 61mutations, specific ddPCR
mutation/wildtype assays (Bio-Rad, #dHsaMDV2010131 and
#dHsaMDV2010133) were used for detection of the two p.Q61H
mutations c.183A>T and c.183A>C. All assays were run according to
the manufacturer's instructions. In general, each PCR reaction was
set up in a total volume of 22 ml with up to 20 ng input DNA, 11 ml 2x
ddPCR Supermix for Probes (no dUTP), 1.1 ml 20x primers/probes
(FAM þ HEX) and nuclease-free water. Droplets were generated
using the QX200 Droplet Generator (Bio-Rad), and the PCR reaction
was then run immediately afterwards with the following program:
95 C for 10 min; 40 cycles of 94 C for 30 s and 55 C for 1 min;
ending with 98 C for 10 min. A ramp rate of 2 C/s was included in
each PCR amplification step. Droplets were read using the QX200
Droplet Reader (Bio-Rad). For each run, a no-template control and
assay-specific positive and negative controls were included.
All samples were run in duplicate or more to achieve 3000
wildtype KRAS-positive droplets. Sample handling was performed
blinded to patient diagnoses, which were disclosed after all KRAS
VAFs had been determined. Data were analyzed by the program
QuantaSoft Analysis Pro 1.0.596 (Bio-Rad) and results were pre-
sented as % variant allele frequency (VAF). Samples with 12,000
droplets generated were excluded from further analysis. Samples
generating a total of 2 mutation-positive droplets or having a VAF
<0.1% were defined as having no detectable tumor DNA.Gender (Male/Female) Mean age at sampling (years ± s.d.)
6/5 50.0 ± 11.7
26/18 53.9 ± 15.4
2/3 55.0 ± 9.1
8/12 54.6 ± 10.9
3/10 37.8 ± 15.3
12/6 59.6 ± 9.3
5/4 48.3 ± 11.0
tis, germline PRSS1 mutation [27] without chronic pancreatitis, cystic fibrosis, and
Fig. 1. Protein and DNA concentration of the 120 duodenal juice samples analyzed
for KRAS mutations. (A) Total protein concentration and (B) total DNA concentration
per ml duodenal juice across different subject groups. Error bars are standard deviation.
(C) Pearson's correlation analysis between total protein and DNA concentration of the
120 samples. MODY8, maturity-onset diabetes of the young, type 8; CP, chronic
pancreatitis; PDAC, pancreatic ductal adenocarcinoma; AP, acute pancreatitis; Other,
other pancreatic disorders; NPGD, nonpancreatic gastrointestinal disease. Controls are
healthy individuals.
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Statistical analyses were conducted in R version 3.6.3 using
Rstudio version 1.1.463 and GraphPad Prism 8.3.0. Pearson's cor-
relation was used to assess the relationship between the total
protein and DNA concentration of duodenal juice, and the concor-
dance between the VAFs of KRAS-positive control pancreatic juice
samples by ddPCR and deep sequencing from our previous study
[10]. Pairwise Mann-Whitney U test was used to assess the differ-
ences in the VAF of KRAS codon 12/13 mutations in relation to
disease type. Linear regression was used to assess the relationship
between the total DNA concentration of nonmalignant duodenal
juice samples positive for KRAS codon 12/13 mutations and the
detected VAF. This method was also used to evaluate the relation-
ship between patient age at sampling and VAF of KRAS codon 12/13
mutations in KRAS-positive subjects with nonmalignant disease.
The likelihood of detection of KRASmutations in subjects50 years
with nonmalignant disease was calculated using the Fisher's exact
test. Except for the Mann-Whitney U test and the Pearson's corre-
lation test, the PDAC cases were excluded from all analyses in order
to avoid a potentially skewed result due to the likely enrichment of
KRAS mutation in these cases.
3. Results
3.1. Protein and DNA concentrations of the duodenal juice samples
We analyzed duodenal juice specimens from 11MODY8 patients
(6 males, 5 females). Age ranged from 34 to 70 years with a mean
value of 50.0 years. For comparison, juice samples were collected
from 100 patients as part of their clinical evaluation for suspected
pancreatic disease. These patients were diagnosed through a
multimodal approach [13] and were subsequently classified into
five diagnosis groups as listed in Table 1. At the time of juice sam-
pling, all disease groups had a mean age between 50 and 60 years
except for the group denoted ‘other pancreatic disorders’, in which
the mean age was 37.8 years. In addition, duodenal juice was
collected from nine healthy individuals (mean age 48.3 years) and
included in the study as a control group.
We first determined the total protein and DNA concentration of
the juice samples. The concentrations observed for the MODY8
subjects were in the same range as for the other patients (Fig. 1A
and B). The mean total protein concentration varied from 1.4 to
2.0 mg/ml for all groups except for other pancreatic disorders where
the concentration was 4.2 mg/ml. The mean concentration of DNA in
the juice samples showed somewhat larger variation between
groups, ranging from 1.0 to 7.2 ng/ml. Notably, no correlation was
observed between the concentration of protein and DNA in the
samples (Pearson's correlation; r ¼ 0.08, p ¼ 0.38; Fig. 1C).
3.2. Detection of KRAS codon 12/13 mutations
KRAS mutation status in codons 12/13 was determined using a
multiplex ddPCR assay, which detects any of seven different mu-
tations in a single reaction. For quality control, we first tested four
pancreatic juice samples obtained from patients with PDAC during
surgery. These samples had been analyzed and identifiedwith KRAS
codon 12 mutations using deep sequencing in a previous study
from our group [10]. We found a high degree of concordance be-
tween the VAF determined by ddPCR and the value previously
estimated by deep sequencing (Pearson's correlation; r ¼ 0.96,
p ¼ 0.04; data not shown).
A KRAS codon 12/13 mutation was then identified in 4/11 (36%)
of the MODY8 samples (Fig. 2A). All KRAS-positive MODY8 patients
were diabetic and had pancreatic exocrine insufficiency. Three of3
them were older than 50 years. The VAFs ranged from 0.15% to
0.35%. No clinical signs of pancreatic cancer were reported in the
KRAS-positive MODY8 patients on subsequent follow-up.
For the other patient groups, the observed frequencies of KRAS
positivity were as follows: CP e 14/44 (32%), PDAC e 3/5 (60%), AP
e 1/20 (5%), other pancreatic disorders e 0/13 (0%), NPGD e 2/18
(11%), healthy controls e 1/9 (11%) (Fig. 2A). Thus, looking collec-
tively at the 120 subjects who had their duodenal juice analyzed by
ddPCR, KRAS codon 12/13 mutations were detected in 25 samples
(21%).
Fig. 2. Detection of KRAS codon 12/13 mutations in 120 duodenal juice samples. (A)
Observed variant allele frequency (VAF) according to disease group and age at sam-
pling. Disease group abbreviations are explained in Fig. 1. (B) Relationship between
total DNA concentration of the duodenal juice samples and KRAS codon 12/13 VAF
modeled by linear regression. (C) Relationship between the age at sampling and KRAS
codons 12/13 VAF modeled by linear regression. Only nonmalignant KRAS-positive
cases (n ¼ 22) were included in (B) and (C).
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0.10% to 0.81%. Linear regression indicated a slightly negative
relationship between the DNA concentration of the duodenal juice
and the VAF of mutant KRAS, although this relationship was not
statistically significant (b ¼ 0.02, p ¼ 0.25; Fig. 2B). When setting
VAFs below 0.1% to zero and including all patients in the statistical
analysis, patients with MODY8 or CP had a significantly lower VAF
compared to patients with PDAC (0.06% vs 0.28%; Mann-Whitney U4
test; p ¼ 0.041). Of note, the only positive case with AP was below
50 years of age and had a relatively high VAF of 0.75%. This patient
had not developed PDAC on subsequent follow-up.
Finally, for the positive cases we analyzed by linear regression
whether there was an association between higher VAF of KRAS
codon 12/13mutations and higher patient age at sampling (Fig. 2C).
This was not the case (b ¼ 0.001, p ¼ 0.117).
3.3. Detection of KRAS codon 61 mutations
Although codon 12/13 alterations represent the by far most
common KRAS point mutations in pancreatic cancer [14], also
codon 61 can be affected. We therefore used two independent
ddPCR assays to evaluate the nonsynonymous mutations c.183A>C
and c.183A>T. These nucleotide substitutions lead to the same
amino acid change in the KRAS protein (p.Q61H) and are the two
most frequent mutations in KRAS codon 61 that are associated with
PDAC [15].
We did not observe the c.183A>C mutation in any of the 120
analyzed specimens although the assay consistently detected this
alteration in two pancreatic juice samples obtained from PDAC
patients during surgery (Fig. 3A). These samples were known from
our previous study to be positive for c.183A>C [10], thereby con-
firming the absence of c.183A>C mutations in the current duodenal
juice material.
For the c.183A>T mutation, one case with MODY8 was positive
with a relatively low VAF of 0.14%. This was, in fact, the only
duodenal juice sample in our material that had a detectable mu-
tation both in codons 12/13 (VAF ¼ 0.35%) and in codon 61. The
double-positive patient was below 50 years at sampling, and the
clinical picture was similar to that of the other MODY8 patients.
Three additional juice samples were positive for c.183A>T: two
stemming fromAP patients and one from a CP patient (Fig. 3B). Two
of the positive subjects were more than 50 years old at the time of
sampling. Unlike the KRAS mutations in codons 12/13, the codon
61-positive cases had VAFs that were above 1% (AP cases: 1.6% and
27.0%; CP case: 21.9%). None of the three subjects with these high
VAFs had developed PDAC at subsequent follow-up.
When the findings of codon 61 mutations were added to the
data for codon 12/13, the KRAS mutation frequencies increased to
15% (3/20) for the AP group and to 34% (15/44) among CP patients.
Taken together, a total of 23% (28/120) KRAS-positive cases were
observed in our material, of which the dominating fraction (89%, 25
subjects) exhibited mutations in codons 12/13.
Excluding the five PDAC cases, we noted that a KRAS codon 12/
13/61 mutation was detected in 26% (18/68) of the individuals with
a sampling age 50 years and in 15% (7/47) of individuals with a
sampling age <50 years. Although this observation could indicate
that older individuals have a higher detection rate of KRAS muta-
tions in duodenal juice, the difference was not statistically different
(Fisher's exact test, two sided; odds ratio ¼ 3.08, p ¼ 0.171).
4. Discussion
In recent years, there has been a growing interest in the po-
tential clinical utility of detecting ctDNA in pancreatic secretions for
surveillance of subjects at high risk of developing PDAC [7e9].
Duodenal juice collected after secretin stimulation originates from
the pancreatic ductal tree where most precancerous lesions of
PDAC arise [16], and it contains DNA and other macromolecules
that probably are released as a result of apoptosis and other cellular
turnover processes [17].
Here we report the first mutation analysis of duodenal juice
from subjects with the MODY8 syndrome [2]. As the disease pro-
gresses, the patients develop pancreatic lipomatosis, atrophy,
Fig. 3. Detection of the KRAS codon 61 mutation Q61H in the duodenal juice
samples. (A) Fluorescence (HEX and FAM) signals of the droplets and examples of
gating different droplet populations in the detection of wildtype KRAS and the p.Q61H
(c.183A>C) mutation using QuantaSoft Analysis Pro (Bio-Rad). Upper panel shows the
gating profile of a pancreatic juice sample from a PDAC patient as positive control,
whereas the lower panel shows the result in a random duodenal juice sample. The
bottom grey population represents droplets without DNA, the green population is
droplets with wildtype KRAS and the blue population is droplets with mutant KRAS. (B)
Detection of the KRAS p.Q61H (c.183A>T) mutation according to disease group and age
at sampling. Disease group abbreviations are explained in Fig. 1. VAF ¼ variant allele
frequency.
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upregulation of target proteins and cytokines of mitogen-activated
protein kinase (MAPK) signaling and an increase in kinase activity
in duodenal juice sampled from subjects with MODY8 [5]. MAPK
acts downstream of the RAS proteins. Moreover, one MODY8 sub-
ject developed PDAC at age 78, before the initiation of the present
study. These observations might indicate a link between MODY8
and pancreatic cancer.
To evaluate a potential association between the two diseases, we
analyzed duodenal juice samples from 11MODY8 patients.We used
the highly sensitive ddPCR technique to determine the abundance
of oncogenic KRAS codon 12/13/61 mutations. For comparison, we
took advantage of juice samples collected from 100 other patients
clinically evaluated for suspected pancreatic disease, as well as
from nine healthy controls. The data were analyzed in relation to
disease type and patient age at sampling. Notably, the detection5
rate of KRAS mutations was nearly identical between subjects with
MODY8 (36%) and CP (34%), and the observed VAFs in KRAS-posi-
tive cases were in the same range (Fig. 2A). Our mutation analysis
therefore did not find evidence for MODY8 subjects having a
greater risk of PDAC development than what is generally observed
in CP. Although subjects with CP have increased PDAC risk, the ef-
fect is modest after long-term follow up, and the large majority of
CP patients do not develop pancreatic cancer [6,18].
In persons without malignant disease, low-frequent KRAS mu-
tations in duodenal juice may originate from and reflect the pres-
ence of benign, low-grade lesions (PanINs) in the pancreatic
parenchyma. These lesions are commonly detected in healthy, aged
individuals, with low potential to progress further into invasive
cancer [19]. It has been reported that KRASmutations are present at
a significantly higher frequency in older than in younger subjects
without pancreatic cancer [7]. In the latter study, among 194
asymptomatic persons with an inherited predisposition to PDAC, a
substantially higher fraction of subjects positive for KRASmutations
(50%) was reported than what we observed in the present work.
The majority of our samples were collected from cases with rela-
tively low risk of PDAC and among the 115 subjects without ma-
lignancy, 22%, (n ¼ 25) were KRAS-positive. We did not observe a
positive relationship between VAF and sampling age (Fig. 2C),
contrasting observations in [7] where screened subjects above 50
years of age had higher mutation concentrations than the younger
subjects.
Notably, in three of our subjects with nonmalignant pancreatic
disorders, unexpected high frequencies of KRAS mutation were
identified. These were two cases with AP and a single case with CP,
all positive for the codon 61 c.183A>T mutation and with no clin-
ically detectable signs of PDAC on subsequent follow-up. Never-
theless, their duodenal juice samples harbored up to 100-fold more
KRAS-mutated DNA than the average VAF (0.28%) observed in our
patients who received a diagnosis of PDAC.We have no explanation
for the high frequency of KRAS mutations observed in these three
cases and can only speculate that inflammatory and/or necrotic
processes somehow have damaged the DNA and made it particu-
larly prone to the codon 61 mutation.
We have previously used deep sequencing to analyze surgically
sampled pancreatic juice from the distal dilated pancreatic duct
and the matched pancreatic head tumor of resectable PDAC pa-
tients [10]. When comparing with the current data, we note a
striking difference between pancreatic and duodenal fluids with
regard to the abundance of KRASmutations. These alterations were
generally present at much lower VAFs (<1%) in the duodenal juice
than in the pancreatic juice sampled during surgery. This was even
true for the patients with PDAC in the present cohort, and the
difference was in the range of 10 to 100-fold (compare with Table 3
of ref. [10]). This discrepancy was unlikely to be caused by different
analytical methods as samples from the previous study tested with
ddPCR yielded comparable VAFs (data not shown). Instead, the low
VAFs in the present study may result from mixing with DNA, both
human and bacterial, originating from the duodenal lumen and
diluting any KRAS mutation present [20]. In fact, there was a
nonsignificant trend towards a negative association between VAF
value and DNA concentration in the duodenal juice samples
(Fig. 2B). A larger number of KRAS-positive samples will be needed
to confirm whether the dilution effect of duodenal juice obtained
after secretin stimulation is a major limiting factor for the detection
of somatic mutations.
Another limitation could be the effect of the collection timing
after secretin stimulation, as this may influence mutation detection
in pancreatic fluids [21]. We used the total protein concentration in
the duodenal juice as a surrogate measure to control for any dif-
ferences in secretion potentially related to the collection timing.We
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the juice but did not find statistical evidence supporting an asso-
ciation (Fig. 1C).
An important difference of our previous report [10] is that we
here used a multiplex assay that detects and reports the sum of
seven common KRAS codon 12/13 mutations. The assay therefore
does not discriminate between individual mutations. It was chosen
due to the limited availability of DNA from each sample which
prevented the detection of each individual mutation in separate
reactions. Our study is also limited by a low number of PDAC cases
with duodenal juice samples available. Hence, we were not able to
investigate any potential link between clinical variables and KRAS
mutations in terms of detection and concentration.
5. Conclusions
We conclude that MODY8 patients do not seem to have a larger
KRASmutational load in their duodenal juice samples than patients
suffering from chronic pancreatitis of other etiologies. Neverthe-
less, our analyses highlight the technical challenges of somatic
mutation detection in duodenal juice: KRASmutations can be found
in subjects with various nonmalignant diseases or even in healthy
individuals, althoughmostly at a low VAF [7e9,20].On the contrary,
such alterations are undetectable in pancreatic secretions of around
20e40% of verified PDAC patients [7,8].
Thus, using KRAS mutational load as a single marker in
pancreatic secretions is currently of very limited clinical utility.
Sensitive methods for detecting multiple somatic mutations [9,22]
in combination with protein markers [23] and epigenetic signa-
tures [24] are probably necessary to potentiate duodenal juice as a
clinically valuable specimen when testing for early pancreatic
cancer.
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